>Mercado de intermediários API da América do Norte, por tipo (intermediários de medicamentos veterinários farmacêuticos/intermediários de medicamentos a granel), produto (composto de bromo, salbutamol O-Benzil, hemisulfato, oxirano, base de bisoprolol, PCBHP quiral, base de feniramina , base de clorfeniramina, base de bromfeniramina, mepiramina/ Base de Pirilamina, 6-Amino-1,3-Dimetil Uracila, Teofilina, Acefilina, Xantina, Nitrilas, Outros), Tipo Terapêutico (Doenças Autoimunes, Oncologia, Doenças Metabólicas, Oftalmologia, Doenças Cardiovasculares, Doenças Infecciosas, Neurologia, Perturbações Respiratórias, Dermatologia , urologia, outras), clientes (utilizadores diretos/empresas farmacêuticas, comerciantes/grossistas/distribuidores, associações/instituições governamentais/instituições privadas), utilizador final (fabricante de API, fabricante de produto acabado), canal de distribuição (licitação direta, vendas a retalho, Outros), País (EUA, Canadá, México) Tendências e previsões da indústria para 2028
Análise e insights de mercado : Mercado de intermediários de API da América do Norte
Espera-se que o mercado norte-americano de intermediários API ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 6,3% no período de previsão de 2021 a 2028 e prevê-se que atinja os 13.491,10 milhões de USD até 2028. A elevada carga de doenças crónicas e o aumento do envelhecimento da população são os principais impulsionadores que impulsionaram a procura do mercado no período de previsão.
Insumo farmacêutico ativo é a substância ou combinação de substâncias destinadas ao fabrico de um medicamento, que quando utilizada na produção do medicamento, se torna um insumo farmacêutico ativo. Tais substâncias são utilizadas para proporcionar atividade farmacológica. A forma farmacêutica final do medicamento é formulada utilizando APIs e excipientes, mas os APIs são formulados utilizando a matéria-prima conhecida como intermediários. Os intermediários API são o tipo de material produzido no processo de API. Os intermediários são subprodutos dos princípios farmacêuticos ativos e proporcionam a mesma atividade terapêutica que os API. Estes intermediários são também utilizados para curar diversos tipos de doenças crónicas, como o cancro, doenças respiratórias e doenças infeciosas, entre outras.
Os intermediários API são os agentes ou compostos utilizados como matéria-prima para a formulação ou produção de insumos farmacêuticos ativos. Estes intermediários sofrem refinamento ou alterações moleculares para formar uma API final. Diferentes tecnologias, como a aminação, alcoxilação, eletroquímica, hidrogenação, hidroformilação, química do acetileno, química do fosgénio e outras tecnologias estão envolvidas na produção de intermediários.
O mercado dos intermediários API está a crescer com o aumento da prevalência de diversas doenças crónicas e o crescente envelhecimento da população. Além disso, o aumento da investigação e desenvolvimento em relação às APIs farmacêuticas e aos seus intermediários são outros fatores que aceleram o crescimento do mercado de intermediários API.
O relatório de mercado de intermediários API fornece detalhes de quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado, aprovações de produtos, decisões estratégicas, lançamentos de produtos, expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado contacte-nos para um resumo do analista, a nossa equipa irá ajudá-lo a criar uma solução de impacto na receita para atingir o objetivo desejado.
Âmbito do mercado e tamanho do mercado de intermediários API da América do Norte
O mercado dos intermediários é segmentado com base no tipo, produto, tipo terapêutico, clientes, utilizadores finais e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo, o mercado de intermediários API está segmentado em intermediários de medicamentos veterinários farmacêuticos/intermediários de medicamentos a granel. Em 2021, prevê-se que os intermediários farmacêuticos/medicamentos a granel dominem o mercado dos intermediários API devido à crescente procura de APIs para a produção de produtos acabados e ao aumento da prevalência de diversas doenças que exigiram a produção contínua de medicamentos.
- Com base no produto, o mercado de intermediários API está segmentado em composto de bromo, O-benzil salbutamol, hemisulfato, oxirano, base de bisoprolol, PCBHP quiral, base de feniramina, base de clorfeniramina, base de bromfeniramina, base de mepiramina/pirilamina , 6-amino-1, 3-dimetiluracilo, teofilina, acefilina, xantina, nitrilos e outros. Em 2021, prevê-se que o segmento das nitrilas domine o mercado dos intermediários API devido ao elevado custo dos produtos e continue a investigação e desenvolvimento para as APIs inovadoras.
- Com base no tipo terapêutico, o mercado dos intermediários API está segmentado em doenças autoimunes , oncologia, doenças metabólicas, oftalmologia, doenças cardiovasculares , doenças infeciosas, neurologia, distúrbios respiratórios, dermatologia , urologia, entre outras. Em 2021, espera-se que o segmento das doenças cardiovasculares domine o mercado dos intermediários API porque as doenças cardiovasculares são a principal causa de morte a nível global.
- On the basis of customers, API intermediates market is segmented direct users/pharma companies, traders/wholesalers/distributors, and associations/govt. institutions/Pvt institutions. In 2021, direct users/pharma companies segment is expected to dominate the API intermediates market because APIs manufacture are the primary and direct user for the intermediates. Rising Contract manufacturing also boost the market.
- On the basis of end user, API intermediates market is segmented into API manufacturer, and finished product manufacturer. In 2021, API manufacturer segment is dominating the API intermediates market because intermediates are the primary chemical substrate of the APIs, which can be further converted in APIs. So, the intermediates is widely used by the API manufacturer to reduce the cost of manufacturing.
- On the basis of distribution channel, API intermediates market is segmented into direct tender, retail sales, and others. In 2021, direct tender is expected to dominate the API intermediates market because direct tender provides huge margin for the purchase good and direct tender has competitive selection of contract and consultants there is accountability.
API intermediates Market Country Level Analysis
The API intermediates market is analyzed and market size information is provided on the basis of type, product, therapeutic type, customers, end users, and distribution channel as referenced above.
The countries covered in the North America API intermediates market report are the U.S, Mexico, Canada.
The U.S is leading the growth of the North America region and pharmaceutical/bulk drug intermediates segment is dominating in this country because the U.S is the highest active pharmaceutical ingredient producer globally. Canada is the fastest growing country due to rising government initiatives for the production of APIs.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Research and Development Regarding Pharmaceutical APIs and their intermediates and Increasing Disease Awareness and Education are boosting the Market Growth of API Intermediates
API intermediates market also provides you with detailed market analysis for every country growth in API intermediates industry with API intermediates drugs sales, impact of advancement in the API intermediates technology and changes in regulatory scenarios with their support for the API intermediates market. The data is available for historic period 2010 to 2019.
Competitive Landscape and API Intermediates Market Share Analysis
API intermediates market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to API intermediates market.
The major companies which are dealing in the North America API intermediates are Cambrex Corporation, AlzChem Group AG, Vasudha Pharma, Anyang General Chemical Co.,Ltd., Sarex, Sandoo Pharmaceuticals and Chemicals Co., Ltd., Atul Ltd, Sandoz International GmbH (a subsidiary of Novartis AG), Aceto, Supriya Lifescience Ltd., Vertellus, Sanofi, Divi's Laboratories Limited, AARTI INDUSTRIES LIMITED, Aurobindo Pharma, BASF SE, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the API intermediates market.
For instance,
- In November 2020, AlzChem Group AG had announced the expansion of the production of the nitriles which is one of the intermediates of the company. The company has decided to expand the production by 50%. The motive behind the company was to support the demand of the medicines and biocides. The nitrile production plant is based on the gas phase technology which has been optimized and validated by the company’s engineers. This expansion has helped the company to enhance their growth in the field of the intermediates which will help them to boost their production capacities.
- In August 2019, Cambrex Corporation had announced that that the company has been acquired by Permira Funds and the company has increase their growth and become one of the premier contract development and manufacturing organization of the drug substances, intermediates and final product. The company was acquired with cash price of USD 60 per share in cash. This agreement helped the company to become as one of the leading company in terms of drug substance, intermediates, analytical services which will increase the company’s customer relationship which will be beneficial for the company’s growth.
A colaboração, o lançamento de produtos, a expansão do negócio, a premiação e o reconhecimento, as joint ventures e outras estratégias do player de mercado estão a melhorar o mercado da empresa no mercado dos intermediários API, o que também oferece o benefício para a organização melhorar a sua oferta de intermediários API .
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA API INTERMEDIATES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET TYPE COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 CURRENT SCENARIO OF IMPORT AND EXPORT OF API INTERMEDIATE
4.2 TENTATIVE PRODUCTION AND OPERATIONAL COSTS CALCULATIONS WHICH WILL ULTIMATELY LEAD TO FEASIBILITY OF THE PRODUCT MANUFACTURING
4.2.1 TENTATIVE LAND REQUIREMENT FOR A SUBSTANTIAL PRODUCTION CAPACITY PLANT SET-UP
4.3 NORTH AMERICA API INTERMEDIATES MARKET: 3C ANALYSIS-CHINA EFFECT
4.3.1 THE U.S.-CHINA TRADE WAR
4.3.2 INDO-CHINA GEOPOLITICAL ISSUES
4.3.3 CHINESE SLOWDOWN DUE TO E&C OVER THE YEARS
4.3.4 CHINESE SLOWDOWN DUE TO COVID-19 (CORONAVIRUS)
4.4 COST ANALYSIS
4.5 ANALYSIS ON CHINA API INTERMEDIATES:
4.5.1 CONCLUSION:
4.6 PORTERS FIVE FORCES MODEL
4.7 PESTEL ANALYSIS
4.8 NORTH AMERICA API INTERMEDIATES MARKET: REGULATORY
4.8.1 THE U.S. REGULATORY GUIDANCE FOR NON-CLINICAL SAFETY EVALUATION OF API INTERMEDIATES
4.8.2 CANADA REGULATORY GUIDANCE FOR API INTERMEDIATES
4.8.3 EUROPE REGULATORY SCENARIO FOR API INTERMEDIATES
4.8.4 JAPAN REGULATORY FOR API INTERMEDIATES
4.8.5 MIDDLE EAST AND AFRICA REGULATORY FRAMEWORK FOR API INTERMEDIATES
5 NORTH AMERICA API INTERMEDIATES MARKET: CONCLUSION
5.1 TOP PRODUCTS AND THERAPEUTIC AREAS
5.2 ADDITIONAL
6 CUSTOMER SENTIMENTS/INCLINATION TOWARDS FINDING ALTERNATE VENDOR SOURCE
7 LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 HIGH BURDEN OF CHRONIC DISEASES
8.1.2 INCREASE IN AGING POPULATION
8.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING
8.1.4 INCREASING DISEASE AWARENESS AND EDUCATION
8.1.5 RESEARCH AND DEVELOPMENT REGARDING PHARMACEUTICAL API AND THEIR INTERMEDIATES
8.2 RESTRAINTS
8.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS
8.2.2 PRODUCT RECALLS
8.2.3 HIGH MANUFACTURING COST
8.2.4 STRINGENT GOVERNMENT REGULATIONS FOR API INTERMEDIATES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
8.3.2 INCREASING HEALTHCARE EXPENDITURE
8.3.3 SOARING NUMBER OF API INTERMEDIATES MANUFACTURERS
8.3.4 RISE IN NUMBER OF CONTRACT MANUFACTURING ORGANIZATIONS (CMO) AND CONTRACT RESEARCH ORGANIZATIONS (CRO)
8.4 CHALLENGES
8.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19
8.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
9 IMPACT OF COVID 19 ON NORTH AMERICA API INTERMEDIATES MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY CHAIIN
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE
9.5 CONCLUSION
10 NORTH AMERICA API INTERMEDIATES MARKET, BY TYPE
10.1 OVERVIEW
10.2 PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES
10.3 VETERINARY DRUG INTERMEDIATES
11 NORTH AMERICA API INTERMEDIATES MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 NITRILES
11.3 BROMO COMPOUND
11.4 CHIRAL PCBHP
11.5 CHLORPHENIRAMINE BASE
11.6 BROMPHENIRAMINE BASE
11.7 PHENIRAMINE BASE
11.8 O-BENZYL SALBUTAMOL
11.9 BISOPROLOL BASE
11.1 HEMISULFATE
11.11 OXIRANE
11.12 MEPYRAMINE/PYRILAMINE BASE
11.13 THEOFYLLINE
11.14 ACEFYLLINE
11.15 XANTHINE
11.16 6-AMINO-1,3-DIMETHYL URACIL
11.17 OTHERS
12 NORTH AMERICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE
12.1 OVERVIEW
12.2 CARDIOVASCULAR DISEASES
12.3 METABOLIC DISEASES
12.4 INFECTIOUS DISEASES
12.5 RESPIRATORY DISEASES
12.6 NEUROLOGY
12.7 ONCOLOGY
12.8 AUTOIMMUNE DISEASE
12.9 DERMATOLOGY
12.1 OPHTHALMOLOGY
12.11 UROLOGY
12.12 OTHERS
13 NORTH AMERICA API INTERMEDIATES MARKET, BY CUSTOMERS
13.1 OVERVIEW
13.2 DIRECT USERS/PHARMA COMPANIES
13.3 TRADERS/WHOLESALERS/DISTRIBUTORS
13.4 ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONS
14 NORTH AMERICA API INTERMEDIATES MARKET, BY END USER
14.1 OVERVIEW
14.2 API MANUFACTURER
14.3 FINISHED PRODUCT MANUFACTURER
15 NORTH AMERICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALE
15.4 OTHERS
16 NORTH AMERICA API INTERMEDIATES MARKET BY GEOGRAPHY
16.1 NORTH AMERICA
16.1.1 U.S
16.1.2 CANADA
16.1.3 MEXICO
17 NORTH AMERICA API INTERMEDIATES MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 AUROBINDO PHARMA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 DIVI’S LABORATORIES LIMITED
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENTS
19.3 BASF SE
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENT
19.4 CAMBRIX CORPORATION
19.4.1 COMPANY SNAPSHOT
19.4.2 COMPANY SHARE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENT
19.6 ACETO
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 HIKAL LTD.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALZCHEM GROUP AG
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENTS
19.9 VERTELLUS
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT CATEGORIES
19.9.3 RECENT DEVELOPMENTS
19.1 SANOFI
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 ATUL LTD
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENTS
19.12 AARTI INDUSTRIES LIMITED
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 VASUDHA PHARMA
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 ANYANG GENERAL CHEMICAL CO., LTD.
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 DISHMAN CARBOGEN AMICS LTD
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORFOLIO
19.15.4 RECENT DEVELOPMENTS
19.16 GANESH-GROUP
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENTS
19.17 LEVACHEM COMPANY LIMITED
19.17.1 COMPANY SNAPSHOT
19.17.2 PRODUCT PORFOLIO
19.17.3 RECENT DEVELOPMENT
19.18 SANDOO PHARMACEUTICALS AND CHEMICALS CO., LTD.
19.18.1 COMPANY SNAPSHOT
19.18.2 PRODUCT PORTFOLIO
19.18.3 RECENT DEVELOPMENT
19.19 SAREX
19.19.1 COMPANY SNAPSHOT
19.19.2 PRODUCT PORTFOLIO
19.19.3 RECENT DEVELOPMENTS
19.2 SUPRIYA LIFESCIENCE LTD.
19.20.1 COMPANY SNAPSHOT
19.20.2 PRODUCT PORTFOLIO
19.20.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
TABLE 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: CUSTOMIZATION (COUNTRIES INVOLVED IN IMPORT & EXPORT)
TABLE 2 PERCENTAGE BREAK UP OF COST
TABLE 3 TENTATIVE LAND REQUIREMENT
TABLE 4 PERCENTAGE BREAK UP OF PLANT AREA
TABLE 5 TABLE: 1 NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS INTERMEDIATES: LIST OF API OR FORMULATION COMPANIES WITH API INTERMEDIATE
TABLE 6 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 7 MARKET PLAYERS OF API INTERMEDIATES
TABLE 8 SALES DATA OF API INTERMEDIATES FOR 2019/2020
TABLE 9 NORTH AMERICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 10 NORTH AMERICA PHARMACEUTICAL INTERMEDIATES/ BULK DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 NORTH AMERICA VETERINARY DRUG INTERMEDIATES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 NORTH AMERICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 13 NORTH AMERICA NITRILES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 NORTH AMERICA BROMO COMPOUND IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 NORTH AMERICA CHIRAL PCBHP IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 NORTH AMERICA CHLORPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 NORTH AMERICA BROMPHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 NORTH AMERICA PHENIRAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 NORTH AMERICA O-BENZYL SALBUTAMOL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 NORTH AMERICA BISOPROLOL BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 NORTH AMERICA HEMISULFATE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 NORTH AMERICA OXIRANE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 NORTH AMERICA MEPYRAMINE/PYRILAMINE BASE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 NORTH AMERICA THEOFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 NORTH AMERICA ACEFYLLINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 NORTH AMERICA XANTHINE IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 NORTH AMERICA 6-AMINO-1, 3-DIMETHYL URACIL IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 NORTH AMERICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 NORTH AMERICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 30 NORTH AMERICA CARDIOVASCULAR DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 31 NORTH AMERICA METABOLIC DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 NORTH AMERICAINFECTIOUS DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 NORTH AMERICA RESPIRATORY DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 NORTH AMERICA NEUROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 NORTH AMERICA ONCOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 NORTH AMERICA AUTOIMMUNE DISEASES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA DERMATOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA OPHTHALMOLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA UROLOGY IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA OTHERS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA DIRECT USERS/PHARMA COMPANIES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA TRADERS/WHOLESALERS/DISTRIBUTORS IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA ASSOCIATIONS/GOVT. INSTITUTIONS/PVT INSTITUTIONSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA API MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 NORTH AMERICA FINISHED PRODUCT MANUFACTURER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 NORTH AMERICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 49 NORTH AMERICA DIRECT TENDER IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 NORTH AMERICA RETAIL SALES IN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 51 NORTH AMERICA OTHERSIN API INTERMEDIATES MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 NORTH AMERICA API INTERMEDIATES MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 53 NORTH AMERICA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 NORTH AMERICA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 55 NORTH AMERICA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 56 NORTH AMERICA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 57 NORTH AMERICA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 58 NORTH AMERICA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 U.S API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 60 U.S API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 61 U.S API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 62 U.S API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 63 U.S API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 U.S API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 CANADA API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 CANADA API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 67 CANADA API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 68 CANADA API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 69 CANADA API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 CANADA API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 MEXICO API INTERMEDIATES MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 MEXICO API INTERMEDIATES MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 73 MEXICO API INTERMEDIATES MARKET, BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
TABLE 74 MEXICO API INTERMEDIATES MARKET, BY CUSTOMERS, 2019-2028 (USD MILLION)
TABLE 75 MEXICO API INTERMEDIATES MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 76 MEXICO API INTERMEDIATES MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
Lista de Figura
FIGURE 1 NORTH AMERICA API INTERMEDIATES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA API INTERMEDIATES MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA API INTERMEDIATES MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA API INTERMEDIATES MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA API INTERMEDIATES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA API INTERMEDIATES MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA API INTERMEDIATES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA API INTERMEDIATES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA API INTERMEDIATES MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA API INTERMEDIATES MARKET: MARKET TYPE COVERAGE GRID
FIGURE 11 NORTH AMERICA API INTERMEDIATES MARKET: SEGMENTATION
FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING IS DRIVING THE NORTH AMERICA API INTERMEDIATES MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PHARMACEUTICAL / BULK DRUG INTERMEDIATES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA API INTERMEDIATES MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF NORTH AMERICA API INTERMEDIATES MARKET
FIGURE 15 TOP 5 COUNTRIES FOR NUMBER OF PEOPLE AGED 20 TO 79 SUFFERING FROM DIABETES IN 2019
FIGURE 16 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN FEMALE POPULATION IN 2020
FIGURE 17 ESTIMATED NUMBER OF DIFFERENT TYPES OF CANCERS IN MALE POPULATION IN 2020
FIGURE 18 NORTH AMERICA CAUSES OF DEATHS WITH THE CHRONIC DISEASES
FIGURE 19 NUMBER OF PERSON AGED 60 YEARS OR OVER BY REGIONS IN 2020 (IN MILLIONS)
FIGURE 20 MARKET GROWTH IN CLINICAL CRO (IN USD MILLIONS)
FIGURE 21 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, 2021
FIGURE 22 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, 2019-2028 (USD MILLION)
FIGURE 23 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 24 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, 2021
FIGURE 26 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, 2019-2028 (USD MILLION)
FIGURE 27 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, CAGR(2021-2028)
FIGURE 28 NORTH AMERICA API INTERMEDIATES MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 29 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2021
FIGURE 30 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, 2019-2028 (USD MILLION)
FIGURE 31 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, CAGR (2021-2028)
FIGURE 32 NORTH AMERICA API INTERMEDIATES MARKET: BY THERAPEUTIC TYPE, LIFELINE CURVE
FIGURE 33 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2021
FIGURE 34 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, 2019-2028 (USD MILLION)
FIGURE 35 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, CAGR (2021-2028)
FIGURE 36 NORTH AMERICA API INTERMEDIATES MARKET: BY CUSTOMERS, LIFELINE CURVE
FIGURE 37 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, 2021
FIGURE 38 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, 2019-2028 (USD MILLION)
FIGURE 39 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, CAGR (2021-2028)
FIGURE 40 NORTH AMERICA API INTERMEDIATES MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 42 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
FIGURE 43 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 44 NORTH AMERICA API INTERMEDIATES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 NORTH AMERICA API INTERMEDIATES MARKET: SNAPSHOT (2020)
FIGURE 46 NORTH AMERICA API INTERMEDIATES MARKET: BY COUNTRY (2020)
FIGURE 47 NORTH AMERICA API INTERMEDIATES MARKET: BY COUNTRY (2021 & 2028)
FIGURE 48 NORTH AMERICA API INTERMEDIATES MARKET: BY COUNTRY (2020 & 2028)
FIGURE 49 NORTH AMERICA API INTERMEDIATES MARKET: BY TYPE (2021-2028)
FIGURE 50 NORTH AMERICA API INTERMEDIATES MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.